ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1513

Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge

Frieda A. Koopman1, Yaakov Levine2, Mike Faltys2, Ralph Zitnik2 and Paul P. Tak3, 1Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2SetPoint Medical Corporation, Valencia, CA, 3Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and therapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cholinergic anti-inflammatory pathway (CAP) activation by electrical vagus nerve stimulation (VNS) is being studied in rheumatoid arthritis (RA) trials (NCT01552941). CAP signaling proceeds sequentially through vagus and splenic nerves to splenic acetylcholine-secreting T cells, which in turn signal adjacent macrophages to diminish cytokine secretion after proinflammatory stilmuli(1). VNS devices depolarize nerves by application of charge, modulated by varying output current (OC), pulse width (PW), and pulse frequency (F). Stimulation duration (D), and daily stimulation interval (SI) can also be varied. Optimally activating this complex neural-immune pathway created unique translational medicine challenges. Herein we report preclinical data guiding stimulation parameter selection for RA trials. 

Methods: VNS stimulation parameter effect on cytokine production and tissue inflammation was studied in 5 models: 1) TNF production in rat systemic endotoxemia with VNS delivered by cervical vagus hook electrodes (HE); 2) morphometric measurement of ulceration in rat indomethacin-induced inflammatory enteritis using cervical vagus cuff electrodes (CE); 3) reduction in in vitro LPS-induced whole blood TNF release using VNS delivered chronically by implanted CE in normal canines; 4) improvement in endoscopic ulceration score after dextran sulfate sodium (DSS) colitis in rats using implanted CE; and 5) improvement in ankle swelling, joint histology and systemic cytokines in rat CIA using implanted CE. 

Results: Selection of PW (200-250usec) and F (10Hz) was guided by prior clinical tolerability experience with VNS in epilepsy(2). OC titration experiments in rat endotoxemia/HE showed optimal CAP activation at 0.5-1.0mA, and was confirmed in canine CE. The implanted CE used in rodent experiments surrounded the entire carotid sheath rather than only the vagus, so correlation experiments in rat endotoxemia with CE vs. HE verified 3.0 mA as optimal OC for chronic rodent models using this peri-carotid CE.  D variation experiments in rat endotoxemia/HE confirmed prior findings(3) that 60 seconds sufficiently activated the CAP. SI experiments in indomethacin enteritis also confirmed prior findings(3)  that a 60 second stimulus caused anti-inflammatory effects persisting for at least 24 hours. Efficacy in rodent subacute DSS colitis and CIA using peri-carotid CE was achieved using 3.0mA OC, 10Hz F, 200usec PW, 60 second D, and once daily SI. For RA trials using peri-vagus CE these same parameters were selected with exception of targeted OC of >1.0mA and 250usec PW.

Conclusion: Preclinical pharmacokinetic-pharmacodynamic-efficacy relationships are typically used to understand dose-response and guide dose selection for drug trials. CAP activation involves complex interactions between neuronal cell depolarization and immune effector cell function, complicating study of analogous stimulation parameter-response relationships. These experiments show that despite these hurdles, rational optimization of therapy delivery with “bioelectronic medicines” can be achieved. 1. Science 2011; 334:98  2. Neurology 2002; 59:S31 3. Crit Care Med 2007; 35:2762


Disclosure:

F. A. Koopman,
None;

Y. Levine,

SetPoint Medical,

3,

SetPoint Medical,

1;

M. Faltys,

SetPoint Medical,

1,

SetPoint Medical,

3;

R. Zitnik,

SetPoint Medical,

3,

SetPoint Medical,

1;

P. P. Tak,

SetPoint Medical,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/selection-of-vagus-nerve-stimulation-parameters-for-a-first-in-human-study-in-rheumatoid-arthritis-a-unique-translational-medicine-challenge/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology